Coronary CT Angiogram: What This Test Actually Measures

What a Coronary CT Angiogram Actually Shows

A CCTA generates high-resolution, cross-sectional images of the coronary arteries after intravenous iodinated contrast injection. The scan captures the arterial lumen, vessel wall, and surrounding cardiac structures during a single breath-hold, synchronized to the patient's ECG so that cardiac motion blur is minimized.

Plaque Detection and Characterization

The test identifies three categories of coronary plaque. Calcified plaque appears as bright white on CT and is quantified by the Agatston calcium score. Non-calcified ("soft") plaque has lower density and may indicate more vulnerable, rupture-prone lesions. Mixed plaque contains both components. A 2022 analysis published in the Journal of the American College of Cardiology confirmed that CCTA-detected low-attenuation plaque volume independently predicts future myocardial infarction, even after adjusting for stenosis severity [1].

Stenosis Grading

Beyond plaque composition, the scan measures how much each plaque narrows the arterial lumen. Stenosis is reported as a percentage of diameter reduction: less than 25% is minimal, 25% to 49% is mild, 50% to 69% is moderate, 70% to 99% is severe, and 100% is total occlusion. The [2022 CAD-RADS 2.0 reporting system](https://pubmed.ncbi.nlm.nih.gov/35## 450161/) standardizes these categories so that referring physicians receive consistent, actionable language regardless of which radiologist reads the scan.

Ancillary Cardiac Findings

CCTA also captures non-coronary structures within the scan field. Readers routinely evaluate the aortic root, cardiac chambers, pericardium, and proximal pulmonary arteries. Incidental findings such as pericardial effusions, valvular calcification, or pulmonary nodules appear in roughly 15% to 25% of scans and may require separate follow-up [2].

The CAD-RADS Classification: How Results Are Reported

The Coronary Artery Disease Reporting and Data System (CAD-RADS) gives clinicians a single category that summarizes overall disease severity and recommended next steps. The Society of Cardiovascular Computed Tomography (SCCT), American College of Radiology (ACR), and the North American Society for Cardiovascular Imaging (NASCI) jointly developed this framework [3].

CAD-RADS Categories Explained

CAD-RADS 0 means zero plaque and zero stenosis. No further cardiac workup is needed. CAD-RADS 1 indicates 1% to 24% stenosis (minimal plaque). Preventive therapy may be considered. CAD-RADS 2 reflects 25% to 49% narrowing and typically triggers lipid management plus lifestyle modification. CAD-RADS 3 (50% to 69% stenosis) often prompts functional testing such as stress echocardiography or fractional flow reserve CT (FFR-CT) to determine hemodynamic significance. CAD-RADS 4A (70% to 99% stenosis in one or two vessels) and CAD-RADS 4B (left main stenosis ≥50% or three-vessel disease ≥70%) generally lead to catheterization referral. CAD-RADS 5 means total occlusion.

Plaque Burden Modifiers

CAD-RADS 2.0 added two modifiers. The "P" modifier flags the presence of non-obstructive but potentially high-risk plaque features: positive remodeling, low-attenuation plaque, napkin-ring sign, or spotty calcification. The "I" modifier flags a non-diagnostic segment that limits interpretation, usually because of motion artifact or heavy calcification.

Coronary Artery Calcium Score: The Companion Measurement

Many CCTA protocols include a non-contrast calcium-scoring acquisition before the contrast-enhanced scan. This Agatston score quantifies total calcified plaque across all coronary territories and has its own prognostic value independent of stenosis.

Interpreting Calcium Scores

A score of 0 Agatston units indicates no detectable calcified plaque and carries an exceptionally low 10-year cardiovascular event rate. The Multi-Ethnic Study of Atherosclerosis (MESA), which followed 6,814 participants for a median of 11.1 years, found that individuals with a baseline CAC of 0 had a 10-year coronary heart disease event rate of approximately 1.1%, compared with 7.1% for scores of 1 to 100 and 23.1% for scores exceeding 300 [4]. Scores above 400 signal extensive calcified disease and place patients in a high-risk category comparable to known coronary artery disease.

When Calcium Scores Mislead

A zero calcium score does not guarantee zero plaque. Younger patients, particularly those under 50, can harbor entirely non-calcified soft plaque that the non-contrast calcium scan cannot detect. The SCOT-HEART trial (N=4,146) demonstrated that CCTA identified non-calcified atherosclerosis in 12% of patients who had a CAC score of zero [5]. This is one reason why the contrast-enhanced angiographic phase is essential for complete assessment.

Who Should Get a Coronary CT Angiogram

CCTA is not a screening test for the general population. Guideline-directed use focuses on specific clinical scenarios where non-invasive coronary imaging changes management.

Chest Pain Evaluation

The 2021 AHA/ACC Chest Pain guideline gives CCTA a Class I recommendation for evaluating acute or stable chest pain in patients with low-to-intermediate pre-test probability of obstructive coronary artery disease [6]. The PROMISE trial (N=10,003) showed that a CCTA-first strategy produced equivalent outcomes to functional stress testing over a median 25-month follow-up, with fewer downstream catheterizations showing non-obstructive disease [7].

Risk Reclassification in Borderline-Risk Patients

The 2019 ACC/AHA Primary Prevention guideline endorses coronary artery calcium scoring (a component of the CCTA protocol) as a decision aid for borderline-risk adults (10-year ASCVD risk 5% to 20%) when the decision to initiate statin therapy is uncertain [8]. A CAC of 0 in this population can reasonably defer statin initiation, while a CAC ≥100 strengthens the case for pharmacotherapy.

Populations Where CCTA Has Limitations

Heavy coronary calcification (Agatston score above 1,000) can create blooming artifact that makes stenosis grading unreliable. Irregular heart rhythms, particularly uncontrolled atrial fibrillation, degrade image quality despite modern motion-correction algorithms. Severe renal insufficiency (eGFR <30 mL/min/1.73 m²) is a relative contraindication because of iodinated contrast risk. And patients with prior coronary stents may have metallic artifact obscuring in-stent evaluation, though newer photon-counting CT scanners are narrowing this gap [9].

How the Test Is Performed

Understanding the acquisition process helps contextualize what the images can and cannot show.

Pre-Scan Preparation

Patients fast for 4 to 6 hours before the exam. Caffeine is restricted for at least 12 hours because it raises heart rate. If resting heart rate exceeds 60 to 65 beats per minute, oral or intravenous beta-blockers (commonly metoprolol 50 to 100 mg orally or 5 to 15 mg IV) are administered to slow the heart and reduce motion artifact. Sublingual nitroglycerin (0.4 to 0.8 mg) is given 3 to 5 minutes before scanning to dilate the coronary arteries and improve lumen visualization.

Image Acquisition

An 18- or 20-gauge IV line is placed, typically in the right antecubital vein. Iodinated contrast (60 to 90 mL at 5 to 6 mL/s) is power-injected, followed by a saline chaser. The scanner performs a timing bolus or uses bolus tracking to capture the contrast peak in the coronary arteries. With prospective ECG gating, the scanner fires X-rays only during the quiescent phase of the cardiac cycle (typically mid-diastole at 70% to 80% of the R-R interval), reducing radiation dose to 1 to 3 mSv on modern 256-slice or wider-detector scanners [10].

Post-Processing and Reporting

Acquired data is reconstructed into axial, multiplanar, maximum-intensity projection, and three-dimensional volume-rendered images. Readers evaluate each coronary segment using the 18-segment model of the coronary tree and assign a CAD-RADS category with appropriate modifiers.

Reading Your Results: A Practical Decision Framework

Many patients receive a CCTA report filled with terminology that their primary care physician must translate into an action plan. The following framework maps CAD-RADS categories to typical clinical pathways.

No Disease (CAD-RADS 0)

No coronary atherosclerosis detected. Standard age-appropriate cardiovascular risk management continues. Repeat imaging is generally not indicated unless new symptoms develop or risk factors change substantially.

Minimal to Mild Disease (CAD-RADS 1-2)

Plaque is present but does not limit blood flow. This is the stage where aggressive preventive therapy has the greatest return. High-intensity statin therapy, blood pressure optimization, HbA1c management in diabetic patients, and smoking cessation form the treatment backbone. The SCOT-HEART trial showed that patients whose CCTA revealed non-obstructive plaque and who received intensified preventive therapy had a 41% lower rate of coronary heart disease death or non-fatal MI over 5 years compared with standard care [5].

Moderate Disease (CAD-RADS 3)

Stenosis of 50% to 69% occupies a gray zone. Anatomic narrowing at this level may or may not restrict flow. FFR-CT (a computational fluid dynamics analysis derived from the CCTA dataset itself) can estimate the hemodynamic significance without additional testing. The PLATFORM trial found that FFR-CT reclassified 61% of patients with CAD-RADS 3 lesions away from invasive catheterization [11].

Severe or Occlusive Disease (CAD-RADS 4-5)

High-grade stenosis (≥70%) or left main disease (≥50%) typically warrants invasive coronary angiography to confirm the findings and plan revascularization. The ISCHEMIA trial (N=5,179) demonstrated that in patients with stable ischemic heart disease and moderate-to-severe ischemia, an initial invasive strategy did not reduce death or MI compared to optimal medical therapy alone over a median 3.2-year follow-up, though it did reduce angina symptoms [12]. This result underscores that even severe anatomic findings do not automatically mandate stenting or bypass surgery.

What CCTA Does Not Measure

A CCTA tells you about anatomy. It does not directly measure blood flow, oxygen delivery, or myocardial viability.

No Functional Flow Data (Without FFR-CT Add-On)

A 60% stenosis on CCTA might or might not cause ischemia depending on collateral supply, lesion length, and distal vessel size. Without FFR-CT computation or a separate stress test, the physiologic significance remains unknown.

No Microvascular Assessment

Coronary microvascular disease, which causes angina in the absence of epicardial stenosis (particularly common in women), is invisible on CCTA. Patients with ongoing symptoms despite a clean CCTA may need invasive coronary function testing with acetylcholine provocation or coronary flow reserve measurement [13].

Limited Soft-Tissue Detail Compared to MRI

Cardiac MRI is superior for evaluating myocardial scar, edema, infiltrative disease, and detailed valvular assessment. CCTA excels at coronary lumen and plaque imaging but is not a substitute for cardiac MRI in non-coronary indications.

Radiation and Safety Considerations

Modern CCTA delivers substantially less radiation than older protocols. Prospective ECG-gated acquisition on a 256-row or wider-detector scanner produces effective doses of 1 to 3 mSv, equivalent to 6 to 18 months of natural background radiation [10]. By comparison, diagnostic invasive coronary angiography delivers 3 to 10 mSv, and nuclear stress testing delivers 6 to 12 mSv.

Contrast Reactions

Allergic-type reactions to iodinated contrast occur in approximately 0.6% of administrations, with severe reactions (anaphylaxis, bronchospasm, cardiovascular collapse) occurring in roughly 0.04% [14]. Patients with documented prior contrast reactions receive premedication with corticosteroids and antihistamines. Contrast-induced nephropathy risk is minimal in patients with eGFR above 45 mL/min/1.73 m² when adequate hydration is maintained.

Pregnancy

CCTA is contraindicated in pregnancy because of ionizing radiation and iodinated contrast (which crosses the placenta). If coronary evaluation is urgent during pregnancy, echocardiography or non-contrast cardiac MRI should be considered first.

Emerging Advances in Coronary CT Imaging

Photon-counting detector CT, approved by the FDA in 2021, generates higher-resolution images with less radiation and fewer metallic artifacts from stents and heavy calcification. Early clinical data from a 2023 Radiology study showed that photon-counting CCTA improved diagnostic confidence in calcified lesions by 23% compared with conventional energy-integrating detectors [15]. CT-derived plaque quantification software can now calculate total plaque volume, percent atheroma volume, and low-attenuation plaque burden from standard CCTA datasets, providing a more granular risk profile than stenosis percentage alone.

Pericoronary fat attenuation index (FAI), measured on standard CCTA images, detects coronary inflammation and has shown promise as an independent predictor of cardiac events. The CRISP-CT study (N=3,912) found that elevated pericoronary FAI around the right coronary artery was associated with a 5.6-fold increase in cardiac mortality, even after adjusting for traditional risk factors and plaque burden [16].